I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ERS 2026

-
Coming soon
09:00 AM
Duration 75mins Barcelona, Spain
The efficacy of astegolimab on COPD hospitalisations: Data from the Phase IIb ALIENTO and Phase III ARNASA trials
MeiLan K. Han

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
09:15 AM
Duration 5mins Barcelona, Spain
The efficacy of astegolimab on COPD hospitalisations: Data from the Phase IIb ALIENTO and Phase III ARNASA trials
MeiLan K. Han

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:30 AM
Duration 90mins Barcelona, Spain
COPD disease trajectories and impact of GOLD E: Danish nationwide cohort study
Anders Løkke

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:15 PM
Duration 75mins Barcelona, Spain
Clinical burden and disease trajectories of newly diagnosed COPD: a real-world retrospective analysis of German insurance claims data
Kathrin Kahnert

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:25 PM
Duration 5mins Barcelona, Spain
Clinical burden and disease trajectories of newly diagnosed COPD: a real-world retrospective analysis of German insurance claims data
Kathrin Kahnert

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
06:00 AM
Duration 90mins Barcelona, Spain
Exploratory eosinophil biomarker analysis from the Phase IIb ALIENTO and Phase III ARNASA trials of astegolimab in COPD
Mona Bafadhel

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 90mins Barcelona, Spain
The efficacy of astegolimab on healthcare resource utilisation– and EXAcerbation of Chronic pulmonary disease Tool– (EXACT) defined COPD exacerbations
Ethan Ashby

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:30 AM
Duration 90mins Barcelona, Spain
Astegolimab reduces sedentary time in patients with COPD: post-hoc analyses from the ALIENTO wearable device–derived physical activity substudy
Neil J. Greening

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar